A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries
Background: The long-term effectiveness of the quadrivalent human papillomavirus (qHPV) vaccine was assessed by monitoring the combined incidence of cervical intraepithelial neoplasia (CIN2, CIN3), adenocarcinoma in situ (AIS), and cervical cancer related to HPV16 or HPV18. Methods: Women from Nordi...
Published in: | Clinical Infectious Diseases |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
2018
|
Subjects: | |
Online Access: | https://curis.ku.dk/portal/da/publications/a-12year-followup-on-the-longterm-effectiveness-of-the-quadrivalent-human-papillomavirus-vaccine-in-4-nordic-countries(0f2101e7-bac0-4de6-964c-8f787cfbe26b).html https://doi.org/10.1093/cid/cix797 |
id |
ftcopenhagenunip:oai:pure.atira.dk:publications/0f2101e7-bac0-4de6-964c-8f787cfbe26b |
---|---|
record_format |
openpolar |
spelling |
ftcopenhagenunip:oai:pure.atira.dk:publications/0f2101e7-bac0-4de6-964c-8f787cfbe26b 2023-07-30T04:04:28+02:00 A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries Kjaer, Susanne K Nygård, Mari Dillner, Joakim Brooke Marshall, J Radley, David Li, Meng Munk, Christian Hansen, Bo T Sigurdardottir, Lara G Hortlund, Maria Tryggvadottir, Laufey Joshi, Amita Das, Rituparna Saah, Alfred J 2018 https://curis.ku.dk/portal/da/publications/a-12year-followup-on-the-longterm-effectiveness-of-the-quadrivalent-human-papillomavirus-vaccine-in-4-nordic-countries(0f2101e7-bac0-4de6-964c-8f787cfbe26b).html https://doi.org/10.1093/cid/cix797 eng eng info:eu-repo/semantics/closedAccess Kjaer , S K , Nygård , M , Dillner , J , Brooke Marshall , J , Radley , D , Li , M , Munk , C , Hansen , B T , Sigurdardottir , L G , Hortlund , M , Tryggvadottir , L , Joshi , A , Das , R & Saah , A J 2018 , ' A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries ' , Clinical infectious diseases : an official publication of the Infectious Diseases Society of America , vol. 66 , no. 3 , pp. 339-345 . https://doi.org/10.1093/cid/cix797 article 2018 ftcopenhagenunip https://doi.org/10.1093/cid/cix797 2023-07-12T23:03:39Z Background: The long-term effectiveness of the quadrivalent human papillomavirus (qHPV) vaccine was assessed by monitoring the combined incidence of cervical intraepithelial neoplasia (CIN2, CIN3), adenocarcinoma in situ (AIS), and cervical cancer related to HPV16 or HPV18. Methods: Women from Nordic countries of Denmark, Iceland, Norway, and Sweden who received a 3-dose regimen of the qHPV vaccine in the beginning of FUTURE II (Females United to Unilaterally Reduce Endo/Ectocervical Disease; V501-015, base study NCT00092534) are followed through different national registries. Effectiveness analyses were conducted approximately 2 years following completion of the base study and occur approximately every 2 years thereafter for 10 years (ie, 14 years from day 1 of the base study). Vaccine effectiveness against HPV16/18-related CIN2 or worse (CIN2+) was estimated by comparing the observed incidence with the expected incidence of CIN2+ in an unvaccinated cohort using historical registry data. Results: In the per-protocol population (2084 women) analysis of effectiveness after the first 12 years, there were no breakthrough cases of HPV16/18 CIN2+ after 9437 person- years of follow-up. Statistical power was sufficient to conclude that qHPV vaccine effectiveness remains above 90% for at least 10 years. The number of person-years during the follow-up interval of 10-12 years is continuing to accrue and shows a trend toward continuing effectiveness of the vaccine during that period. Conclusion: The qHPV vaccine shows continued protection in women through at least 10 years, with a trend for continued protection through 12 years of follow-up. Clinical Trials Registration: NCT00092534. Study Identification: V501-015. Article in Journal/Newspaper Iceland University of Copenhagen: Research Norway Clinical Infectious Diseases 66 3 339 345 |
institution |
Open Polar |
collection |
University of Copenhagen: Research |
op_collection_id |
ftcopenhagenunip |
language |
English |
description |
Background: The long-term effectiveness of the quadrivalent human papillomavirus (qHPV) vaccine was assessed by monitoring the combined incidence of cervical intraepithelial neoplasia (CIN2, CIN3), adenocarcinoma in situ (AIS), and cervical cancer related to HPV16 or HPV18. Methods: Women from Nordic countries of Denmark, Iceland, Norway, and Sweden who received a 3-dose regimen of the qHPV vaccine in the beginning of FUTURE II (Females United to Unilaterally Reduce Endo/Ectocervical Disease; V501-015, base study NCT00092534) are followed through different national registries. Effectiveness analyses were conducted approximately 2 years following completion of the base study and occur approximately every 2 years thereafter for 10 years (ie, 14 years from day 1 of the base study). Vaccine effectiveness against HPV16/18-related CIN2 or worse (CIN2+) was estimated by comparing the observed incidence with the expected incidence of CIN2+ in an unvaccinated cohort using historical registry data. Results: In the per-protocol population (2084 women) analysis of effectiveness after the first 12 years, there were no breakthrough cases of HPV16/18 CIN2+ after 9437 person- years of follow-up. Statistical power was sufficient to conclude that qHPV vaccine effectiveness remains above 90% for at least 10 years. The number of person-years during the follow-up interval of 10-12 years is continuing to accrue and shows a trend toward continuing effectiveness of the vaccine during that period. Conclusion: The qHPV vaccine shows continued protection in women through at least 10 years, with a trend for continued protection through 12 years of follow-up. Clinical Trials Registration: NCT00092534. Study Identification: V501-015. |
format |
Article in Journal/Newspaper |
author |
Kjaer, Susanne K Nygård, Mari Dillner, Joakim Brooke Marshall, J Radley, David Li, Meng Munk, Christian Hansen, Bo T Sigurdardottir, Lara G Hortlund, Maria Tryggvadottir, Laufey Joshi, Amita Das, Rituparna Saah, Alfred J |
spellingShingle |
Kjaer, Susanne K Nygård, Mari Dillner, Joakim Brooke Marshall, J Radley, David Li, Meng Munk, Christian Hansen, Bo T Sigurdardottir, Lara G Hortlund, Maria Tryggvadottir, Laufey Joshi, Amita Das, Rituparna Saah, Alfred J A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries |
author_facet |
Kjaer, Susanne K Nygård, Mari Dillner, Joakim Brooke Marshall, J Radley, David Li, Meng Munk, Christian Hansen, Bo T Sigurdardottir, Lara G Hortlund, Maria Tryggvadottir, Laufey Joshi, Amita Das, Rituparna Saah, Alfred J |
author_sort |
Kjaer, Susanne K |
title |
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries |
title_short |
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries |
title_full |
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries |
title_fullStr |
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries |
title_full_unstemmed |
A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries |
title_sort |
12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries |
publishDate |
2018 |
url |
https://curis.ku.dk/portal/da/publications/a-12year-followup-on-the-longterm-effectiveness-of-the-quadrivalent-human-papillomavirus-vaccine-in-4-nordic-countries(0f2101e7-bac0-4de6-964c-8f787cfbe26b).html https://doi.org/10.1093/cid/cix797 |
geographic |
Norway |
geographic_facet |
Norway |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
Kjaer , S K , Nygård , M , Dillner , J , Brooke Marshall , J , Radley , D , Li , M , Munk , C , Hansen , B T , Sigurdardottir , L G , Hortlund , M , Tryggvadottir , L , Joshi , A , Das , R & Saah , A J 2018 , ' A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries ' , Clinical infectious diseases : an official publication of the Infectious Diseases Society of America , vol. 66 , no. 3 , pp. 339-345 . https://doi.org/10.1093/cid/cix797 |
op_rights |
info:eu-repo/semantics/closedAccess |
op_doi |
https://doi.org/10.1093/cid/cix797 |
container_title |
Clinical Infectious Diseases |
container_volume |
66 |
container_issue |
3 |
container_start_page |
339 |
op_container_end_page |
345 |
_version_ |
1772815925489172480 |